The stock of Dexcom Inc (DXCM) has gone up by 0.89% for the week, with a -15.15% drop in the past month and a -11.33% drop in the past quarter. The volatility ratio for the week is 3.29%, and the volatility levels for the past 30 days are 3.58% for DXCM. The simple moving average for the past 20 days is -12.64% for DXCM’s stock, with a -14.68% simple moving average for the past 200 days.
Is It Worth Investing in Dexcom Inc (NASDAQ: DXCM) Right Now?
The price-to-earnings ratio for Dexcom Inc (NASDAQ: DXCM) is 50.08x, which is above its average ratio. Moreover, the 36-month beta value for DXCM is 1.49. Analysts have varying opinions on the stock, with 17 analysts rating it as a “buy,” 4 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for DXCM is 385.17M and currently, short sellers hold a 2.56% of that float. On March 18, 2025, DXCM’s average trading volume was 3.81M shares.
DXCM) stock’s latest price update
Dexcom Inc (NASDAQ: DXCM) has seen a rise in its stock price by 0.93 in relation to its previous close of 70.69. However, the company has experienced a 0.89% gain in its stock price over the last five trading sessions. zacks.com reported 2025-03-14 that DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising competition pose challenges.
Analysts’ Opinion of DXCM
Many brokerage firms have already submitted their reports for DXCM stocks, with Redburn Atlantic repeating the rating for DXCM by listing it as a “Buy.” The predicted price for DXCM in the upcoming period, according to Redburn Atlantic is $115 based on the research report published on February 03, 2025 of the current year 2025.
Robert W. Baird, on the other hand, stated in their research note that they expect to see DXCM reach a price target of $104, previously predicting the price at $86. The rating they have provided for DXCM stocks is “Outperform” according to the report published on January 16th, 2025.
Robert W. Baird gave a rating of “Neutral” to DXCM, setting the target price at $80 in the report published on July 26th of the previous year.
DXCM Trading at -14.59% from the 50-Day Moving Average
After a stumble in the market that brought DXCM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.75% of loss for the given period.
Volatility was left at 3.58%, however, over the last 30 days, the volatility rate increased by 3.29%, as shares sank -19.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.26% lower at present.
During the last 5 trading sessions, DXCM rose by +0.89%, which changed the moving average for the period of 200-days by -43.99% in comparison to the 20-day moving average, which settled at $81.67. In addition, Dexcom Inc saw -8.26% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DXCM starting from Heller Bridgette P, who proposed sale 352 shares at the price of $70.33 back on Mar 17 ’25. After this action, Heller Bridgette P now owns shares of Dexcom Inc, valued at $24,756 using the latest closing price.
Leach Jacob Steven, the EVP, Chief Operating Officer of Dexcom Inc, sale 14,076 shares at $70.38 during a trade that took place back on Mar 12 ’25, which means that Leach Jacob Steven is holding 313,497 shares at $990,670 based on the most recent closing price.
Stock Fundamentals for DXCM
Current profitability levels for the company are sitting at:
- 0.15 for the present operating margin
- 0.6 for the gross margin
The net margin for Dexcom Inc stands at 0.14. The total capital return value is set at 0.17. Equity return is now at value 27.63, with 9.04 for asset returns.
Based on Dexcom Inc (DXCM), the company’s capital structure generated 0.55 points at debt to capital in total, while cash flow to debt ratio is standing at 0.39. The debt to equity ratio resting at 1.2. The interest coverage ratio of the stock is 31.58.
Currently, EBITDA for the company is 840.7 million with net debt to EBITDA at 2.1. When we switch over and look at the enterprise to sales, we see a ratio of 7.39. The receivables turnover for the company is 4.01for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.47.
Conclusion
To wrap up, the performance of Dexcom Inc (DXCM) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
